Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study

• Published in: Annals of surgery Vol. 248; no. 2; p. 145
• Main Authors: Linehan, David C, Tan, Marcus C B, Strasberg, Steven M, Drebin, Jeffrey A, Hawkins, William G, Picus, Joel, Myerson, Robert J, Malyapa, Robert S, Hull, Michael, Trinkaus, Kathryn, Tan, Jr, Benjamin R
• Format: Journal Article
• Language: English
• Published: United States 01.08.2008
• Subjects: Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - therapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatectomy - methods; Pancreatic Neoplasms - mortality; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - therapy; Probability; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Time Factors

This is a phase II, single-center, single-arm study of patients with resectable adenocarcinoma of the pancreas who were treated with adjuvant interferon-based chemoradiation followed by gemcitabine. The primary end point was 2-year overall survival, with secondary endpoints being 2-year disease-free...